By understanding CD8 + T cell dysregulation and exhaustion in the tumor microenvironment (TIME), we can overcome the TEX barrier and improve immune checkpoint blockade therapies in the clinic, regardless of whether the type of tumor is the same or different (Kurtulus et al., 2019). The gene discussed is CD8A; the disease is neoplasm.